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Background: The Transforming growth factor β (TGFβ) signaling has a paradoxical role in cancer development
and outcome. Besides, the prognostic significance of the TGFβ1, SMAD4 in breast cancer patients is an area of
many contradictions. The transcriptional intermediary factor 1γ (TIF1γ) is thought to interact with the TGFβ/SMAD
signaling through different mechanisms. Our study aims to define the prognostic significance of TGFβ1, SMAD4
and TIF1γ expression in breast cancer patients and to detect possible interactions among those markers that
might affect the outcome.
Methods: Immunohistochemistry was performed on tissue microarray (TMA) blocks prepared from samples of
248 operable breast cancer patients who presented at Centre Léon Bérard (CLB) between 1998 and 2001. The
intensity and the percentage of stained tumor cells were integrated into a single score (0–6) and a cutoff was
defined for high or low expression for each marker. Correlation was done between TGFβ1, SMAD4 and TIF1γ
expression with the clinico-pathologic parameters using Pearson’s chi-square test. Kaplan-Meier method was used
to estimate distant metastasis free survival (DMFS), disease free survival (DFS) and overall survival (OS) and the
difference between the groups was evaluated with log-rank test.
Results: 223 cases were assessable for TIF1γ, 204 for TGFβ1 and 173 for SMAD4. Median age at diagnosis was
55.8 years (range: 27 to 89 years). Tumors were larger than 20 mm in 49.2 % and 45.2 % had axillary lymph node
(LN) metastasis (N1a to N3). 19.4 % of the patients had SBR grade I tumors, 46.8 % grade II tumors and 33.9 %
grade III tumors. ER was positive in 85.4 %, PR in 75.5 % and Her2-neu was over-expressed in 10 % of the cases.
Nuclear TIF1γ, cytoplasmic TGFβ1, nuclear and cytoplasmic SMAD4 stainings were high in 35.9 %, 30.4 %, 27.7 %
and 52.6 % respectively. TIF1γ expression was associated with younger age (p = 0.006), higher SBR grade
(p < 0.001), more ER negativity (p = 0.035), and tumors larger than 2 cm (p = 0.081), while TGFβ1 was not
associated with any of the traditional prognostic factors.
TGFβ1 expression in tumor cells was a marker of poor prognosis regarding DMFS (HR = 2.28; 95 % CI: 1.4 to 3.8;
p = 0.002), DFS (HR = 2.00; 95 % CI: 1.25 to 3.5; p = 0.005) and OS (HR = 1.89; 95 % CI: 1.04 to 3.43; p = 0.037).
TIF1γ expression carried a tendency towards poorer DMFS (p = 0.091), DFS (p = 0.143) and OS (p = 0.091).
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In the multivariate analysis TGFβ1 remained an independent predictor of shorter DMFS, DFS and OS.
Moreover, the prognostic significance of TGFβ1 was more obvious in the TIF1γ high patient subgroup than in the
patients with TIF1γ low expression. The subgroup expressing both markers had the worst DMFS (HR = 3.2; 95 %
CI: 1.7 to 5.9; p < 0.0001), DFS (HR = 3.02; 95 % CI: 1.6 to 5.6; p < 0.0001) and OS (HR = 2.7; 95 % CI: 1.4 to 5.4; p = 0.005).
Conclusion: There is a crosstalk between the TIF1γ and the TGFβ1/SMAD4 signaling that deteriorates the outcome of
operable breast cancer patients and when combined together they can serve as an effective prognostic tool for those
patients.Background
Transforming growth factor-beta (TGFβ) belongs to a
superfamily of polypeptides that controls cell proliferation,
differentiation, motility and apoptosis in different cell
types [1]. TGFβ1, one of the 3 isoforms of TGFβ, is a
potent negative regulator of mammary gland epithelial
cell proliferation [2, 3]. Several studies have demonstrated
that TGFβ1 regulates many steps of normal mammary
gland development and plays an important role in breast
carcinogenesis [1, 4].
TGFβ signaling was proven to have dual role in cancer
development as it displays both tumorigenic and tumor-
suppressive effects. In early stages of tumor development
TGFβ signaling suppresses tumor formation by its anti-
proliferative and anti-apoptotic effects and the loss of TGFβ
signaling was found to be one of the drivers of breast
malignancy initiation. On the other hand, in later stages of
carcinogenesis TGFβ1 signaling promotes metastasis by
promoting epithelial-to-mesenchymal transition (EMT),
angiogenesis and immunosuppression [4–6].
TGFβ signaling is triggered by binding of TGFβ to its
receptor with the dimerization of TGFβ type I and II recep-
tors (TβRIIs) leading to phosphorylation of the receptor
regulated (R-) SMAD2 and SMAD3. Phosphorylated
SMADs combine with common mediator (co-) SMAD4
that migrates to the nucleus. The SMAD complexes inter-
act with different transcription factors regulating several
target genes that control proliferation, metabolism
and migration of malignant cells [7] . Besides this classical
TGFβ/SMAD signaling, other SMAD independent sig-
naling pathways also exist such as activation of mitogen
activated protein kinases (MAPK) [8].
The transcriptional intermediary factor 1γ (TIF1γ), is a
ubiquitous nuclear protein that has been implicated in
TGFβ signaling through its binding to phosphorylated
Smad2/3 [9]. TIF1γ could also antagonize Smad4 through
its ubiquitin ligase activity [10]. We have recently demon-
strated that TIF1γ regulates the TGFβ-induced EMT in
mammary epithelial cells and during terminal differenti-
ation of mammary alveolar epithelial cells and lactation
through repression of Smad4 activity [11–13]. Most of data
from mouse models suggest a tumor suppressor role for
TIF1γ [14–16]. However, a recent study has demonstratedthat overexpression of TIF1γ occurs during the early stages
of colorectal carcinogenesis, suggesting a role in promoting
colorectal cancer [17].
Expression of the TGFβ pathway markers in breast cancer
revealed highly contradictory results. On one hand several
studies observed that higher TGFβ1 levels in tumors or in
the blood of breast cancer patients could predict a better
outcome and less distant metastases [18–20]. On the other
hand, several other studies reported that TGFβ1 expression
carries a poor prognosis in those patients [21, 22].
In this retrospective study we analyzed the pattern of
expression of TGFβ1, SMAD4 and TIF1γ in breast cancer
tumors. We further analyzed the prognostic significance
of each marker and the effect of the interactions between
those 3 key players of the TGFβ signaling pathway on the
outcome of breast cancer patients that might explain the
contradictory results from the literature.
Methods
Patient population
We screened 353 consecutive female patients with operable
primary breast cancer who underwent radical surgery and
received adjuvant/neoadjuvant therapy at Centre Léon
Bérard (CLB) between January 1998 and December 2001.
Paraffin blocks of tumor tissue were available for 320
patients. Among these, we failed to assess any of the
biomarker staining in 61 tumor specimens as a result of
insufficient tumor or tissue loss during tissue microarray
(TMA) preparation. Therefore, specimens from 259
patients with operable primary breast cancer were ana-
lyzed in this study. 11 patients were not included in the
analysis as they were discovered to have metastatic disease
at the initial diagnosis. In the remaining 248 samples (due
to further tissue loss during slide preparation), 223 cases
were assessable for TIF1γ, 204 cases for TGFβ1 and 173
cases for SMAD4 expression. A flowchart of the whole
population and subsets tested for different biomarkers is
shown in Additional file 1: Figure S1.
Patients underwent either modified radical mastectomy,
or breast-conserving surgery. Lymph node invasion was
assessed by axillary sentinel node and/or level I and II
lymph node dissection and the number of lymph nodes
(LNs) harboring metastasis was determined based on
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maximum tumor diameter measured on the tumor speci-
mens at the time of surgery. Estrogen receptors (ER) and
progesterone receptors (PgR) were detected by immuno-
histochemistry and tumors were considered positive if they
had a nuclear staining in 10 % or more of the tumor cells.
Human epidermal growth factor receptor 2 (HER2) expres-
sion was determined using immunohistochemistry and
tumors were considered positive if they had 3+ staining
by immunohistochemistry or 2+ staining with Her-2
amplification detected by FISH.
The data exported from the patients’ files for analysis
included: age, histologic subtype, maximum tumor size,
number of LNs involved, SBR grade, ER, PgR expression,
HER2 overexpression, date of diagnosis, date of relapse,
date of death and date of last news. This study is reported
according to the REMARK criteria [23] and was done ac-
cording to French regulations and approved by the ethics
committee of the Centre Léon Bérard.
Immunohistochemical analysis
Breast tumour samples were inserted as triplicates using
a 600 μm needle in 8 Tissue Micro Array (TMA) blocks.
The blocks containing invasive carcinoma were sectioned
at a thickness of 4 μm. After deparaffinization and rehydra-
tion, endogenous peroxidases were blocked by incubating
the slides in 5 % hydrogen peroxide in sterile water. For
heat induced antigen retrieval, tissue sections were boiled
in 10 mM Citrate Buffer pH6 (Dako, Trappes, France)
using a water bath at 98 °C for 50 minutes.
The slides were then incubated at room temperature for
60 minutes with the antibodies against TGFβ1 (mouse
monoclonal antibody MCA797 clone TB21 from AbD
Serotec, Munich, Germany), TIF1γ (mouse monoclonal
antibody TIF3E9 clone from Euromedex), SMAD4 (mouse
monoclonal antibody SC-7966 clone B-8 from Santa Cruz,
TX, USA).
These antibodies were diluted using an antibody diluent
solution (Chemmate, Dako, Trappes, France) at 1/100
(for anti-TGFβ1), 1/500 (for anti-TIF1γ), 1/250 (for
anti-SMAD4). After rinsing in Phosphate Buffer Saline, the
slides were incubated either with a biotinylated secondary
antibody bound to a streptavidin peroxidase conjugate
(LSAB+ Kit, Dako, Trappes, France) for anti-TGFβ1 and
SMAD4 or with the Flex kit (Ref K800021-2, Dako, Trappes,
France) for anti- TIF1γ antibody. Bound antibody was
revealed by adding the substrate 3, 3-diamino-benzidine.
Sections were counterstained with hematoxylin.
Blinded to the clinical data, the biomarkers expression
was evaluated by 2 observers who assessed both the per-
centage and the intensity of cytoplasmic staining for TGFβ1
and SMAD4 and of nuclear staining for TIF1γ and SMAD4
in the infiltrative carcinomatous cells only. For scoring pur-
poses, the highest intensity of staining in malignant cellswas classified into 4 levels (0: no staining, 1: weak staining,
2: moderate staining, 3: strong staining) and the percentage
of the stained cells was also classified into 4 levels (0: no
stained cells, 1: staining in less than one third of the malig-
nant cells, 2: staining in one to two thirds of the malignant
cells, 3: staining in more than two thirds of the malignant
cells). Then both the intensity and the percentage scores were
added to conclude a single score (from 0 to 6) in a manner
similar to the Allred score for ER and PR staining [24].
For the purpose of correlations and survival analyses,
tumours were considered to have low expression of
cytoplasmic TGFβ1, and nuclear or cytoplasmic SMAD4
if they had a score of 0–2 and were considered to have
high expression if they had a score of more than 2, while
tumours were considered as nuclear TIF1γ low if they
had a score of 0–3 and were considered as TIF1γ high if
they had a score more than 3. Choice of the cut-off for
high or low biomarker expression was based on the most
discriminative cut-off in terms of survival analysis. Finally,
patients were considered to have total SMAD4 low
(SMAD4 loss) if they had low or no expression of both
nuclear and cytoplasmic SMAD4.
Statistical analysis
The correlation between TIF1γ, TGFβ1, SMAD4 expres-
sion and clinico-pathologic characteristics, was determined
using Pearson’s chi square test (or Fisher’s exact test) for
categorical variables and Student’s T test for numerical vari-
ables. Disease-free survival (DFS) was defined as the time
from the date of diagnosis of breast cancer to the date of
any cancer recurrence (local or distant or contralateral), or
death. Distant metastasis free survival (DMFS) was defined
as the time from the date of diagnosis of breast cancer to
the date of distant metastasis or death. Overall survival
(OS) was defined as the time from the date of diagnosis of
breast cancer to the date of death.
To account for the heterogeneous follow up period
resulting from different dates of diagnoses and last
follow up visits, we locked the database at a maximum of
12 years of follow up and patients without events at 12 years
were censored.
Survival curves, median DMFS, DFS and OS (if reached)
in addition to 8 year DMFS, DFS and OS rate (with 95 %
CIs) were derived from Kaplan-Meier estimates and the
curves were compared using log-rank test [25]. Hazard
ratios and 95 % CIs were calculated using cox regression
model [26]. Cox multivariate analysis was performed using
cox regression model to determine whether a factor is an
independent predictor of DMFS, DFS or OS after
adjusting for other significant factors at the univariate
level. All statistical tests were two-sided, and the p value
was considered statistically significant if less than 5 %.
The statistical analyses were performed using SPSS 17.0
statistics package (SPSS Inc, Chicago, IL).
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Clinico-pathological characteristics
For the 248 assessable patients the median follow up
interval was 9.7 years (range: 2 m to 12y). Median
age at diagnosis was 55.8 years (range: 27 to 89 years).
49.2 % had tumors larger than 20 mm, 45.2 % had
LN metastasis. 19.4 % of the patients had SBR grade
I tumors, 46.8 % grade II tumors and 33.9 % grade
III tumors. ER was positive in 85.4 %, PR in 75.5 %
and Her2-neu was over-expressed in 10 % of the
cases. 56.5 % of the patients received adjuvant
chemotherapy while 77.4 % received adjuvant hor-
monal therapy. Additional file 1: Table S1 shows the





Fig. 1 Representative images of immunohistochemical stainings showing t
high c and low d expression of TGFβ1, Tumor cells with high expression e
f and Tumor cells with high expression g of cytoplasmic SMAD4Expression profile of TIF1γ, TGFβ1 and SMAD4
Representative images of immunohistochemical stainings
showing tumor cells with high and low expression of dif-
ferent markers are shown in Fig. 1. TIF1γ was high in 80
cases (35.9 %) (Fig. 1a) while 143 cases (64.1 %) showed
low expression (Fig. 1b). TGFβ1 showed high expression
in 62 (30.4 %) (Fig. 1c) while 142 cases (69.6 %) showed
low expression (Fig. 1d).
Nuclear SMAD4 was high in 48 cases (27.7 %) (Fig. 1e)
and low in 125 cases (72.3 %) while cytoplasmic SMAD4
was high in 91 cases (52.6 %) (Fig. 1g) and low in 82
cases (47.4 %). Low expression of both nuclear and
cytoplasmic SMAD4 (SMAD4 loss) was detected in
70 patients (40.5 %) of the 173 patients (Fig. 1f ). No
correlation could be detected between the expressionB
D
F
umor cells with high a and low b expression of TIF1γ, Tumor cells with
of nuclear SMAD4, low expression of nuclear and cytoplasmic SMAD4
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sion of SMAD4 (Additional file 1: Table S2).
High TIF1γ expression and loss of SMAD4 are associated
with poor prognostic factors
The correlations between clinical parameters and different
predictive and prognostic factors with TGFβ1, TIF1γ and
SMAD4 expression are shown in Table 1.
TGFβ1 expression was not correlated to any of the
traditional prognostic markers such as age, tumor size,
SBR grade, axillary lymph node metastasis, ER, PR, and
HER2 status. Interestingly, high TIF1γ expression was
associated with younger age (p = 0.006), higher SBR
grade (p < 0.001), ER negativity (p = 0.035), and a tendency
towards larger tumors (p = 0.08).
Loss of SMAD4 expression (cytoplasmic or nuclear)
was associated with higher tumor SBR grade (p = 0.004)
and more ER negativity (p = 0.02), while the nuclear
localization of SMAD4 was not associated with any of
the clinico-pathological parameters.
High expression of TGFβ1 and TIF1γ are associated with
poor clinical outcome
TGFβ1 expression was associated with more deaths
(30.4 % of patients with high expression died versus
17.6 % in patients with low expression, p = 0.04),
more disease recurrences (35.5 % of patients with
high expression versus 17.6 % in patients with low
expression, p = 0.005), and more metastatic relapses
(33.9 % of patients with high expression versus 14.1 % in
patients with low expression, p = 0.001).
TIF1γ expression (as a single marker) also showed
similar trends towards increased number of deaths
and distant metastases however, not reaching statistical
significance. The loss of SMAD4 expression did not cor-
relate with more deaths or relapses. Death and relapse
events in correlation with the biomarkers expression are
shown in Table 2.
Of interest, the pattern of distant metastases was corre-
lated with the 3 biomarkers expression. For example among
the 10 patients having bone only metastases, 9 of them
expressed SMAD4 (in the nucleus or cytoplasm) while only
one patient had no SMAD4 expression (p = 0.050). On the
other hand, patients co-expressing TGFβ1 and TIF1γ
had more chance of visceral metastases than the rest
of the patients population (24.2 % versus 7.3 %, p = 0.002),
while such tendency did not appear for bone metastases
(p = 0.74).
Regarding the patients’ survival, DMFS was shorter in
patients highly expressing TGFβ1 than those with low
expression with an 8y DMFS rate of 62.5 % (95 % CI:
46.5-78.5 %) compared to 83.2 % (95 % CI: 76–90.4 %)
respectively (p = 0.001). DFS was also shortened in
high TGFβ1 patients with an 8y DFS rate of 63.5 %(95 % CI: 46.5-78.5 %) versus 82.1 % (95 % CI: 74.7-89.4 %)
in the low expression group (p = 0.004). OS was worse in
cases with high TGFβ1 expression with an 8y OS rate
of 75 % (95 % CI: 61.9-88.1 %) versus 84.7 % (95 %
CI: 77.8-91.6 %) in the TGFβ1 low group (p = 0.03). Fig. 2
shows the Kaplan Meier’s curves for DMFS, DFS and OS
according to different biomarker expression.
According to the Cox proportional hazard model
high TGFβ1 expression almost doubled the risk of
developing distant metastases (HR = 2.28, 95 % CI: 1.4
to 3.8, p = 0.002), and death by 80 % (HR = 1.89, 95 %
CI: 1.04 to 3.43, p = 0.037).
Regarding the effect of the classical prognostic factors,
DMFS was shorter with tumors larger than 2 cm (HR= 2.61,
95 % CI: 1.59 to 4.30, p = 0.0002), axillary LN involvement
(HR= 2.02, 95 % CI: 1.26 to 3.26, p = 0.004), High SBR grade
(HR= 2.61, 95 % CI: 1.64 to 4.16, p = 0.00006), ER negative
(HR= 2.36, 95 % CI: 1.35 to 4.12, p = 0.003), and PR negative
tumors (HR= 1.72, 95 % CI: 1.042 to 2.85, p = 0.03).
Importantly, in the multivariate analysis, when adjusted
to tumor size, lymph node positivity, SBR grade, ER and
PR status, TGFβ1 expression was still an independent
predictor for distant metastasis (HR = 2.56, 95 % CI: 1.5 to
4.3, p < 0.0001) and death (HR = 2.06; 95 % CI: 1.13 to
3.75, p = 0.018). In addition to TGFβ1, large tumor size
(HR = 2.10, 95 % CI: 1.25 to 3.49, p = 0.005) and high SBR
grade (HR = 1.97, 95 % CI: 1.16 to 3.36, p = 0.013) were
the only factors that independently predicted shorter
DMFS in the multivariate model.
For TIF1γ expression there was a tendency towards
increased risk of metastasis (HR = 1.54; 95 % CI: 0.93
to 2.54, p = 0.09), and death (HR = 1.6; 95 % CI: 0.9 to 2.8,
p = 0.09) in cases of high TIF1γ expression compared to
cases with low expression.
SMAD4 expression (including nuclear localization)
showed no prognostic significance for DMFS, DFS or OS.
Prognostic significance of TGFβ1 is limited to more
advanced tumor stages
Interestingly, the effect of TGFβ1 expression on the out-
come of breast cancer was observed to be limited to tumors
with higher T and N stages. For example, in tumors smaller
than 20 mm in the maximal dimension, the 8 years DFS
rate was 86.7 % (95 % CI: 76.7-96.7 %) in patients with low
TGFβ1 expression versus 86.3 % (95 % CI: 73.2-99.3 %) in
patients with high TGFβ1 (p = 0.91). In larger tumors how-
ever, the 8 years DFS rate was 79.2 % (95 % CI: 64.1-91.3 %)
versus 43.7 % (95 % CI: 16.7-70.7 %) in patients with low
versus high TGFβ1 expression respectively (p = 0.0003).
Similarly, in patients with no axillary LN metastasis
the 8 years DFS rate was 84.9 % (95 % CI: 74.9-94.9 %)
versus 75.5 % (95 % CI: 57.6-93.4 %) in patients with low
versus high TGFβ1 expression respectively (p = 0.31). On
the other hand, in patients with axillary LN metastasis,
Table 1 Correlation between nuclear TIF1γ, cytoplasmic TGFβ1and SMAD4 expression with the clinico-pathologic parameters of
breast cancer
Variable TIF1γ low TIF1γ high Pa TGFβ1 low TGFβ1 high Pa SMAD4 low SMAD4 high Pa
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
143 (64.1) 80 (35.9) 142 (69.6) 62 (30.4) 70 (40.5) 103 (59.5)
Age (Yr) -Mean (± SD) 59.4(±12) 55.9(±13) 0.048b 57.6(±12) 59.3(±14) 0.37b 56.5(±12) 57.1 (±12) 0.74b
Age groups - ≤50y 37 (26) 35 (44) 0.006 44 (31) 21 (34) 0.68 22 (31) 38 (37) 0.46
- >50y 106 (74) 45 (56) 98 (69) 41 (66) 48 (69) 65 (63)
Side -Right 68 (48) 37 (46) 0.85 62 (44) 28 (45) 0.84 30 (43) 51 (49) 0.39
-Left 75 (52) 43 (54) 80 (56) 34 (55) 40 (57) 52 (51)
T. size - ≤2 cm 80 (56) 35 (44) 0.08 73 (51) 30 (48) 0.69 31 (44) 51 (49) 0.49
- >2 cm 63 (44) 45 (56) 69 (49) 32 (52) 39 (56) 52 (51)
LN met -Negative 85 (59) 41 (51) 0.24 79 (56) 35 (57) 0.91 36 (51) 55 (53) 0.79
-Positive 58 (41) 39 (49) 63 (44) 27 (44) 34 (49) 48 (47)
SBR grade -Gr 1 39 (27) 6 (7) <0.001 30 (21) 11 (18) 0.82 5 (7) 26 (25) 0.004
-Gr 2 72 (50) 30 (38) 63 (44) 30 (48) 35 (50) 50 (49)
-Gr 3 32 (23) 44 (55) 49 (35) 21 (34) 30 (43) 27 (26)
ER status -Negative 13 (9) 15 (19) 0.035 24 (17) 6 (10) 0.17 13 (19) 7 (7) 0.02
-Positive 129 (91) 64 (81) 116 (83) 56 (90) 56 (81) 95 (93)
PR status -Negative 28 (20) 22 (28) 0.18 38 (27) 11 (18) 0.14 18 (26) 21 (21) 0.40
-Positive 113 (80) 57 (72) 101 (73) 51 (82) 51 (74) 81 (79)
Her 2 status -Negative 126 (91) 69 (87) 0.35 125 (91) 54 (89) 0.66 60 (90) 90 (89) 0.93
-Over-expressed 12 (9) 10 (13) 13 (9) 7 (11) 7 (10) 11 (11)
Breast cancer subtype -Luminal 127 (91) 64 (81) 0.12c 114 (83) 55 (90) 0.31c 54 (81) 94 (93) 0.05c
-Her2 rich 2 (1) 3 (4) 4 (3) 2 (3) 2 (3) 1 (1)
-Basal 11 (8) 12 (15) 20 (14) 4 (7) 11 (16) 6 (6)
(Neo)/ Adjuv. Hormonal ttt -Tamoxifen 101 (89) 54 (87) 0.89c 95 (92) 44 (83) 0.20c 48 (89) 75 (94) 0.48c
-AI 4 (4) 3 (5) 3 (3) 2 (4) 1 (2) 1 (1)
-Tamoxifen + AI 8 (7) 5 (8) 5 (5) 7 (13) 5 (9) 4 (5)
(Neo)/ Adjuv. chemotherapy -Anthra. 52 (85) 40 (82) 0.61 58 (76) 25 (83) 0.59 34 (74) 44 (80) 0.48c
only 9 (15) 9 (18) 16 (21) 5 (17) c 11 (24) 11 (20)
-Anthra. + 1 (2) 0 (0)
Taxane 0 (0) 0 (0) 2 (3) 0 (0)
-Others
aCorrelations tested by Pearson’s Chi square test (2sided) unless otherwise specified
b Difference between means by Student’s T test
c Fisher’s exact test
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versus 50.0 % (95 % CI: 20.8 %-79.2 %) in patients with
low versus high TGFβ1 expression respectively (p = 0.001).
Kaplan Meier curves for DFS in TGFβ1 high versus low
expression in early (T size ≤ 20 mm and LN negative) and
advanced (T size > 20 mm and LN positive) stages are
presented in Fig. 3.
TIF1γ restricts the prognostic significance of TGFβ1
Strikingly, the ability of TGFβ1 expression to predict
the poor outcome in breast cancer patients was restrictedto TIF1γ expressing tumors. For example, in the patient
population with TIF1γ high expression the 8y DMFS
rate was 49.2 % (95 % CI: 16.3-80.8 %) in patients with high
TGFβ1 expression versus 82.7 % (95 % CI: 79.2-94.2 %) in
patients with TGFβ1 low expression (p = 0.009). On the
other hand, in the patient population with TIF1γ low
expression the 8y DMFS rate was 78.1 % (95 % CI:
65.9-90.2 %) versus 85.9 % (95 % CI: 75.5-96.3 %) in high
versus low TGFβ1 respectively (p = 0.2). The same pattern
of difference was also observed in DFS and OS as shown
in Kaplan Meier curves in Fig. 4.
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Fig. 2 Kaplan Meier plots for the impact of low (Dotted blue) versus high (green) expression of TGFβ1 a, b, c, TIF1γ d, e, f and SMAD4 g, h, i on
DMFS a, d, g, DFS b, e, h and OS c, f, i in breast cancer patients
Table 2 Death, relapse, and metastatic events in correlation with TIF1γ and TGFβ1 expression
Events TIF1γ low TIF1γ high P* TGFβ1 low TGFβ1 high P* SMAD4 low SMAD4 high P*
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
143 (64.1) 80 (35.9) 142 (69.6) 62 (30.4) 70 (40.5) 103 (59.5)
Death -Alive 115 (80) 57 (71) 0.11 117 (82) 43 (69) 0.04 56 (80) 82 (80) 0.95
-Dead 28 (20) 23 (29) 25 (18) 19 (31) 14 (20) 21 (20)
Recurrence -No 113 (79) 59 (74) 0.37 117 (82) 40 (65) 0.005 56 (80) 78 (76) 0.51
-Yes 30 (21) 21 (26) 25 (18) 22 (35) 14 (20) 25 (24)
DistantMetast. -No 118 (83) 60 (75) 0.18 122 (86) 41 (66) 0.001 58 (83) 81 (79) 0.49
-Yes 25 (17) 20 (25) 20 (14) 21 (34) 12 (17) 22 (21)
*Correlations tested by Pearson’s Chi square test
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Fig. 3 Kaplan Meier curves for DFS of TGFβ1 low (Dotted blue) versus high (green) expression in patients with tumors≤ 20 mm a, > 20 mm b,
N0-1mic c and N1a-3 d
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TGFβ1 and TIF1γ had the poorest prognosis when
compared to the rest of the patients' population. The
8 years DMFS, DFS and OS rates were 49.2 % (95 % CI:
16.3-80.8 %), 48.3 % (95 % CI: 15.2-75.3 %) and 59.1 %
(95 % CI: 29.8-88.4 %) in the TGFβ1-high/TIF1γ-high
subgroup versus 82.4 % (95 % CI: 75.2-89.8 %), 81.8 %
(95 % CI: 74.4-89.2 %) and 85.3 % (95 % CI: 91.2-79.4 %)
in the rest of the population (P < 0.001, <0.001 and =0.003
respectively). Kaplan Meier curves of DMFS, DFS and OS
of this subgroup are shown in Fig. 5.
According to Cox regression model the co-expression
of TGFβ1 and TIF1γ increased the risk of metastases(HR = 3.2; 95 % CI: 1.7 to 5.9, p < 0.0001), any recurrence
(HR = 3.02; 95 % CI: 1.6 to 5.6, p < 0.0001) and death
from any cause (HR = 2.7; 95 % CI: 1.4 to 5.4, p = 0.005).
In the multivariate analysis, and when adjusted to
age, SBR grade, tumor size, and lymph node invasion
the co-expression of TGFβ1 and TIF1γ remained an
independent poor prognostic factor that predicted metas-
tasis, any recurrence and death from any cause.
TIF1γ strongly predicts relapse and death in patients with
SMAD4 loss
Low expression of SMAD4 appeared to manipulate the
outcome of patients withTIF1γ high versus low expression.
81                   74                     53         43
34                   27                     22         16
47               39                     33          24
22               14 9            6
81     74                     53         43
34                     27                     22         16
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22               15                      9          6
81                     76              59         48
34       29               25         17
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Fig. 4 Kaplan Meier plots for DMFS a, b, DFS c,d and OS e, f of TGFβ1 high (green) versus low expression (Dotted blue) in TIF1γ low patients a, c, e
and TIF1γ high patients b, d, f
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Fig. 5 Kaplan Meier curves showing the DMFS a, DFS b and OS c of the TGFβ1-high/TIF1γ-high patients (green) versus the rest of patient
population (Dotted blue)
Kassem et al. BMC Cancer  (2015) 15:453 Page 10 of 13In patients with SMAD4-low tumors, TIF1γ expression
strongly predicted metastasis, any cancer recurrence and
death, while in patients with SMAD4 high expression, the
TIF1γ expression did not show any prognostic value. In pa-
tients with SMAD4 loss, the 8 years DMFS rate was 66.2 %
(95 % CI: 41.2-91.2 %) in patients with high TIF1γ versus
93.9 % (95 % CI: 82.9-100 %) in patients with low TIF1γ (p
= 0.001), while it was 77.2 % (95 % CI: 60.0-94.4 %) versus
81.0 % (95 % CI: 70.5-91.5 %) respectively (p = 0.96) in the
SMAD4 expressing group. Similarly, DFS and OS showed
the same difference only in patients with low SMAD4 ex-
pression (p = 0.006 and 0.004 respectively) while such dif-
ferences were absent with high SMAD expression (p = 0.39
and 0.40 respectively). Figure 6 shows Kaplan Meier curves
for DMFS, DFS and OS in patients with TIF1γ high versus
low expression according to SMAD4 status of the tumors.
Discussion
In our present work we found a definitive poor outcome
in patients whose primary breast tumors showed higher
expression of cytoplasmic TGFβ1. Those patients had an
increased risk of metastasis and death and this risk was
independent from the other major prognostic factors
such as tumor size, LN involvement, SBR grade and
hormone receptor status. The poor outcome in those
patients was restricted to patients with larger tumors
(more than 2 cm) and axillary lymph node metastasis
(N1a-N3), an observation that might be explained by
the dual role of TGFβ signaling in different stages of
carcinogenesis.
Our results are in agreement with the work of Des-
ruisseau et al. who reported that a high TGFβ1 protein
level measured by enzyme-immunoassay in breast cancer
tissue was an independent poor prognostic marker for
disease free survival [21]. Richardsen et al. also reported
that high stromal expression of TGFβ in breast cancer
areas was associated with increased mortality. [22].
However, other studies showed opposing results withbetter DFS and OS in patients with high TGFβ1 and
TGFβ receptor type II expression [18] and lower recurrence
rates with patients expressing TGFβ1 and pSMAD2/3 [20].
Our data may help to provide explanations for some
of the discrepancies in the results of previous studies
testing TGFβ1/SMAD4 pathway biomarkers expression.
Such discrepancies might be explained by the different
effect of TGFβ1 expression in early versus advanced
tumor stages, the heterogeneous population included in
such retrospective trials and the crosstalk between TGFβ
signaling and other pathways. Indeed in our study, we
also observed a significant interaction between TGFβ1,
TIF1γ expression and the prognosis of breast cancer
patients, an interaction that was not investigated in
previous studies. The subgroup of patients expressing
both TGFβ1 and TIF1γ showed the poorest outcome
compared to the rest of the patient population. Finally,
the different scoring systems for biomarker staining in
those studies may account for this diversity, putting into
account what was suggested by Bierie et al. that gain
or complete loss of TGFβ signaling may result in gene
expression signatures correlated with poor prognosis in
breast cancer [27].
On the other hand, TIF1γ expression showed tendency
towards poor outcome in breast cancer patients. That ten-
dency became significant when combined with TGFβ1
expression and SMAD4 loss. To our knowledge this is the
first study to report such interactions which might be
unexpected in view of the available data suggesting a role
for TIF1γ in inhibiting epithelial to mesenchymal transi-
tion (EMT) through repression of SMAD4 activity and
hence interfering with tumor progression and metastasis
[11]. This tumor inhibitory role was also observed against
murine and human tumors including pancreatic, hepato-
cellular carcinomas and leukemia [14–16]. However,
our findings are in agreement with the observation by
Jain et al. that overexpression of TIF1γ was associated
with colorectal cancer incidence and poor prognosis [17].
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Fig. 6 Kaplan Meier curves of DMFS a, b, DFS c, d and OS e, f curves for TIF1γ high (green) versus low expression (Dotted blue) in cases of
SMAD4 loss a, c, e and SMAD4 expression b, d, f
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find any correlation between SMAD4 expression and
any of the clinico-pathological parameters of breast
cancer. We did not find also any prognostic significance
of either nuclear localization or total loss of SMAD4
expression. This may be concordant with some studies
that tested the effect of SMAD4 expression in operable
breast cancer [28].
On the other hand 2 important observations were
found regarding SMAD4 expression. The first is the
presence of a significant interaction between TIF1γ and
SMAD4 that alters the patients’ outcome regarding
distant metastases and overall survival. We have shown
that TIF1γ predicts poor outcome of breast cancer
patients only in cases with SMAD4 loss, while in breast
cancer patients whose tumors expressed SMAD4 no
difference in survival was detected. The idea of combining
SMAD4 loss with other biomarkers expression was tack-
led in a study by De Kruijf et al. combining SMAD4 loss
with the expression of TGFβ type I & II receptors that
could identify a subgroup of stage I to III breast cancer
carrying the poorest outcome [29].
The second observation was the strong association
between SMAD4 expression and the pattern of relapse
of breast cancer. Almost all patients with only bone
metastasis expressed SMAD4 either in the cytoplasm
or the nucleus. Such observation are in accordance
with previous studies, in xenograft models and cell
lines, showing that SMAD4 signaling is needed for the
formation of osteolytic bone metastases, an observation
that was confirmed by the knockdown of SMAD4 in
breast cancer cells which could protect against bone
metastasis in nude mice with significantly increasing
metastasis free survival [30, 31].
Surprisingly, we found a poor outcome in patients
with co-expression of TIF1γ with either TGFβ1 high
or SMAD4 low. A possible hypothesis is that TIF1γ
competes with SMAD4 turning off the SMAD4
dependent TGFβ signaling. Such dual effect of the
TGF-β signaling might be influenced by the varying
TIF1γ/Smad4 ratios resulting in the modulation of
the transcriptional signal induced by TGFβ as suggested
by Andrieux et al. [32]. We cannot also exclude that
tumor-cell-derived TGFβ acts on the surrounding tissue
in a paracrine manner instead of an autocrine signaling in
the tumor cells themselves. Interactions between tumor
cells and cancer-associated fibroblasts (CAFs) in the
tumor microenvironment significantly influence cancer
growth and metastasis, and TGFβ is known to be crit-
ical for CAF activation and elaboration of a pro-
tumorigenic microenvironment [6].
Our work, however is limited by its retrospective nature,
the use of TMA sections that bear only cores of the whole
tumor, the absence of a validation of our results in anindependent cohort (preferably in multiple centers) in
addition to the heterogeneity of the patient cohort regarding
the adjuvant treatment received which may bias the results.
Larger prospective biomarker-oriented studies are needed to
further clarify the missing pieces of the TGF pathway story.
Conclusion
Our present work clearly concludes that there is a cross-
talk between the TIF1γ and the TGFβ1/SMAD4 pathway
that can predict poorer outcome in operable breast cancer
patients. Such prediction of poor outcome was more evi-
dent in tumors with higher stages. We could also conclude
that the value of TGFβ1, SMAD4 and TIF1γ expression in
breast cancer should not be considered individually but in-
stead combined to serve as an effective prognostic tool for
breast cancer. The value of such information is of utmost
importance with the introduction of new targeted agents
against the TGFβ axis [33–35]. The upcoming trials test-
ing those agents in breast cancer represent a golden op-
portunity for clearly understanding the impact of this
pathway on the disease outcome in addition to finding
biomarkers that could predict benefit of such drugs.
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